Clinical and patient reported treatment outcomes of livedoid vasculopathy: A systematic review.
Mackenzie O GippleShannon K ThrockmortonVirginia B GaboKyaw Zin HtetAlex G Ortega LoayzaPublished in: Clinical and experimental dermatology (2024)
Livedoid vasculopathy (LV) is a rare condition affecting the lower extremities, often linked to hypercoagulable states or vascular disorders, and despite increasing treatment options, patients frequently experience suboptimal outcomes. Our systematic review of 44 studies, involving 216 patients, found that Rivaroxaban was the most common treatment, with complete (n=18, 31%) or partial (n=40, 68%) ulcer healing and complete pain resolution in the 19% reported, while IVIG also showed promise, though results were mixed. The review highlights the need for further research to identify optimal treatments for LV and establish a standard of care for future clinical trials.
Keyphrases
- end stage renal disease
- systematic review
- patient reported
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- prognostic factors
- peritoneal dialysis
- chronic pain
- venous thromboembolism
- randomized controlled trial
- patient reported outcomes
- pulmonary embolism
- pain management
- spinal cord injury
- skeletal muscle
- metabolic syndrome
- big data
- study protocol
- combination therapy
- weight loss